CGT
AMAG

Capital Guardian Trust’s AMAG Pharmaceuticals AMAG Stock Holding History

Capital Guardian Trust’s Portfolio AMAG Stock Details AMAG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-38
Closed -$1K – 801
2016
Q1 		$1K Buy
+38
New +$902 ﹤0.01% 786

Other funds holding AMAG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
SIM
Stelliam Investment Management New York $404M AUM 5.1% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Capital Guardian Trust's AMAG Position: Q2 2016 in Review

Capital Guardian Trust sold out of AMAG Pharmaceuticals (AMAG) in Q2 2016, closing a stake of 38 shares — an estimated $1K sold.

Capital Guardian Trust first reported a position in AMAG in Q1 2016 and held it in 1 quarter. The position peaked at $1K in Q1 2016. 165 funds tracked by Wall St. Rank hold AMAG as of Q2 2016.

  • Capital Guardian Trust reported no remaining AMAG Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • Capital Guardian Trust sold 38 AMAG Pharmaceuticals shares in Q2 2016, an estimated $1K.
  • Capital Guardian Trust first reported a position in AMAG Pharmaceuticals in Q1 2016 and held it in 1 quarter.
  • Capital Guardian Trust's AMAG Pharmaceuticals position peaked at $1K in Q1 2016.
  • 165 funds tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q2 2016.

Based on Capital Guardian Trust's 13F filing for Q2 2016, filed 15 Aug 2016.